Literature DB >> 22678915

Subcellular localization of FOXP3 in human regulatory and nonregulatory T cells.

Thomas Magg1, Joachim Mannert, Joachim W Ellwart, Irene Schmid, Michael H Albert.   

Abstract

The transcriptional regulator FOXP3 is an important determinant of regulatory T (Treg) cell development and function and is frequently used to quantitate Treg cells. However, FOXP3 is also expressed in recently activated conventional human T cells. Here, we investigated the FOXP3 expression patterns in Treg and activated T cells at a cellular level. Upon activation, human CD4(+) CD25(-) T cells expressed FOXP3 mainly in the cytoplasm, in sharp contrast to human CD4(+) CD25(+) Treg cells, where we found FOXP3 to be predominantly expressed in the nucleus. A GFP-FOXP3-fusion protein shuttled from the nucleus to the cytoplasm in transfected primary human T cells. We identified two novel leucine-rich nuclear export signals in FOXP3. Site-directed mutagenesis of both sequences completely abolished nuclear export of FOXP3 in human T cells. Both export sequences localized to exons affected by alternative splicing. The three isoforms FOXP3Δ2, FOXP3Δ7, and FOXP3Δ2Δ7 localized preferentially to the nucleus. Additionally, forced expression of nucleus-directed FOXP3 induced a Treg-cell-associated gene expression pattern and induced regulatory capacity. These findings should aid in the interpretation of future studies utilizing FOXP3 expression as a Treg-cell marker and shed some light on the molecular mechanisms controlling subcellular FOXP3 localization in human T cells.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22678915     DOI: 10.1002/eji.201141838

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  27 in total

1.  Eosinophils from eosinophilic oesophagitis patients have T cell suppressive capacity and express FOXP3.

Authors:  C Lingblom; J Wallander; M Ingelsten; H Bergquist; M Bove; R Saalman; A Welin; C Wennerås
Journal:  Clin Exp Immunol       Date:  2016-12-06       Impact factor: 4.330

2.  MiRNome and transcriptome aided pathway analysis in human regulatory T cells.

Authors:  M H Albert; J Mannert; K K Fleischmann; M Schiemann; P Pagel; I Schmid; T Magg
Journal:  Genes Immun       Date:  2014-05-22       Impact factor: 2.676

3.  Association of colonic regulatory T cells with hepatitis C virus pathogenesis and liver pathology.

Authors:  Helal F Hetta; Mohamed A Mekky; Nasr K Khalil; Wegdan A Mohamed; Mohamed A El-Feky; Shabaan H Ahmed; Enas A Daef; Mahmoud I Nassar; Ahmed Medhat; Kenneth E Sherman; Mohamed Tarek M Shata
Journal:  J Gastroenterol Hepatol       Date:  2015-10       Impact factor: 4.029

4.  FoxP3 scanning mutagenesis reveals functional variegation and mild mutations with atypical autoimmune phenotypes.

Authors:  Ho-Keun Kwon; Hui-Min Chen; Diane Mathis; Christophe Benoist
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-21       Impact factor: 11.205

5.  Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.

Authors:  Donald T Weed; Paolo Serafini; Jennifer L Vella; Isildinha M Reis; Adriana C De la Fuente; Carmen Gomez; Zoukaa Sargi; Ronen Nazarian; Joseph Califano; Ivan Borrello
Journal:  Clin Cancer Res       Date:  2014-10-15       Impact factor: 12.531

6.  Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.

Authors:  Bryan D Choi; Patrick C Gedeon; James E Herndon; Gary E Archer; Elizabeth A Reap; Luis Sanchez-Perez; Duane A Mitchell; Darell D Bigner; John H Sampson
Journal:  Cancer Immunol Res       Date:  2013-09       Impact factor: 11.151

7.  Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease.

Authors:  M M Imanguli; E W Cowen; J Rose; S Dhamala; W Swaim; S Lafond; B Yagi; R E Gress; S Z Pavletic; F T Hakim
Journal:  Leukemia       Date:  2014-02-28       Impact factor: 11.528

8.  Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients.

Authors:  Minesh Mehta; Helal F Hetta; Enass A Abdel-Hameed; Susan D Rouster; MdMonir Hossain; Mohamed A Mekky; Nasr K Khalil; Wegdan A Mohamed; Mohamed A El-Feky; Shabaan H Ahmed; Enas A Daef; Mohamed A El-Mokhtar; Sayed F Abdelwahab; Ahmed Medhat; Kenneth E Sherman; Mohamed Tarek M Shata
Journal:  Arch Virol       Date:  2016-08-20       Impact factor: 2.574

9.  A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.

Authors:  William W Greenfield; Shawna L Stratton; Rebecca S Myrick; Rita Vaughn; Lisa M Donnalley; Hannah N Coleman; Maria Mercado; Andrea M Moerman-Herzog; Horace J Spencer; Nancy R Andrews-Collins; Wilbur C Hitt; Gordon M Low; Nirvana A Manning; Samantha S McKelvey; Dora Smith; Michael V Smith; Amy M Phillips; C Matthew Quick; Susanne K Jeffus; Laura F Hutchins; Mayumi Nakagawa
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

10.  FOXP3 protects conventional human T cells from premature restimulation-induced cell death.

Authors:  Kelsey Voss; Camille Lake; Christopher R Luthers; Nathaniel M Lott; Batsukh Dorjbal; Swadhinya Arjunaraja; Bradly M Bauman; Anthony R Soltis; Gauthaman Sukumar; Clifton L Dalgard; Andrew L Snow
Journal:  Cell Mol Immunol       Date:  2019-10-28       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.